NervGen Pharma Q2 EPS Forecast Decreased by HC Wainwright

NervGen Pharma (NASDAQ:NGEN) – Stock analysts at HC Wainwright decreased their Q2 2026 earnings estimates for shares of NervGen Pharma in a research report issued to clients and investors on Tuesday, July 14th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.09). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for NervGen Pharma’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.56) EPS.

NervGen Pharma (NASDAQ:NGEN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

A number of other analysts also recently weighed in on the stock. Weiss Ratings assumed coverage on shares of NervGen Pharma in a research report on Friday, April 24th. They set a “sell (d-)” rating for the company. Leerink Partners started coverage on shares of NervGen Pharma in a report on Monday. They set an “outperform” rating and a $10.00 price objective for the company. TD Cowen assumed coverage on shares of NervGen Pharma in a research note on Thursday, June 11th. They issued a “buy” rating on the stock. Stifel Nicolaus upgraded NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Finally, Wall Street Zen lowered NervGen Pharma from a “hold” rating to a “sell” rating in a report on Sunday. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NervGen Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

NervGen Pharma Stock Performance

NASDAQ:NGEN opened at $1.69 on Thursday. The firm has a market capitalization of $136.27 million and a PE ratio of -18.78. NervGen Pharma has a one year low of $1.68 and a one year high of $6.30. The stock has a 50-day simple moving average of $2.36.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.